Literature DB >> 27181836

Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.

Alptug Karakucuk1, Nevin Celebi2, Zeynep Safak Teksin1.   

Abstract

The objective of this study was to prepare ritonavir (RTV) nanosuspensions, an anti-HIV protease inhibitor, to solve its poor water solubility issues. The microfluidization method with a pre-treatment step was used to obtain the nanosuspensions. Design of Experiment (DoE) approach was performed in order to understand the effect of the critical formulation parameters which were selected as polymer type (HPMC or PVP), RTV to polymer ratio, and number of passes. Interactions between the formulation variables were evaluated according to Univariate ANOVA. Particle size, particle size distribution and zeta potential were selected as dependent variables. Scanning electron microscopy, X-ray powder diffraction, and differential scanning calorimetry were performed for the in vitro characterization after lyophilization of the optimum nanosuspension formulation. The saturation solubility was examined in comparison with coarse powder, physical mixture and nanosuspension. In vitro dissolution studies were conducted using polyoxyethylene 10 lauryl ether (POE10LE) and biorelevant media (FaSSIF and FeSSIF). The results showed nanosuspensions were partially amorphous and spherically shaped with particle sizes ranging from 400 to 600nm. Moreover, 0.1-0.4 particle size distribution and about -20mV zeta potential values were obtained. The nanosuspension showed a significantly increased solubility when compared to coarse powder (3.5 fold). Coarse powder, physical mixture, nanosuspension and commercial product dissolved completely in POE10LE; however, cumulative dissolved values reached ~20% in FaSSIF for the commercial product and nanosuspension. The nanosuspension showed more than 90% drug dissolved in FeSSIF compared to the commercial product which showed ~50% in the same medium. It was determined that RTV dissolution was increased by nanosuspension formulation. We concluded that DoE approach is useful to develop nanosuspension formulation to improve solubility and dissolution rate of RTV. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DoE; HPMC; Microfluidization; Nanosuspension; Ritonavir

Mesh:

Substances:

Year:  2016        PMID: 27181836     DOI: 10.1016/j.ejps.2016.05.010

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

Review 1.  Bioavailability Enhancement of Poorly Water-Soluble Drugs via Nanocomposites: Formulation⁻Processing Aspects and Challenges.

Authors:  Anagha Bhakay; Mahbubur Rahman; Rajesh N Dave; Ecevit Bilgili
Journal:  Pharmaceutics       Date:  2018-07-08       Impact factor: 6.321

2.  Development and Validation of an HPLC Method Using an Experimental Design for Analysis of Amlodipine Besylate and Enalapril Maleate in a Fixed-dose Combination

Authors:  Diren Sarısaltık Yaşın; Alev Arslantürk Bingül; Alptuğ Karaküçük; Zeynep Şafak Teksin
Journal:  Turk J Pharm Sci       Date:  2021-06-18

Review 3.  Design Space and QbD Approach for Production of Drug Nanocrystals by Wet Media Milling Techniques.

Authors:  Leena Peltonen
Journal:  Pharmaceutics       Date:  2018-07-25       Impact factor: 6.321

Review 4.  Microfluidization trends in the development of nanodelivery systems and applications in chronic disease treatments.

Authors:  Palanivel Ganesan; Govindarajan Karthivashan; Shin Young Park; Joonsoo Kim; Dong-Kug Choi
Journal:  Int J Nanomedicine       Date:  2018-10-09

Review 5.  Progress in the development of stabilization strategies for nanocrystal preparations.

Authors:  Jingru Li; Zengming Wang; Hui Zhang; Jing Gao; Aiping Zheng
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

6.  Development of Nanocrystal Compressed Minitablets for Chronotherapeutic Drug Delivery.

Authors:  Nagaraja Sreeharsha; Nimbagal Raghavendra Naveen; Posina Anitha; Prakash S Goudanavar; Sundarapandian Ramkanth; Santosh Fattepur; Mallikarjun Telsang; Mohammed Habeebuddin; Md Khalid Answer
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.